Enliven therapeutics announces updated positive data from phase 1 clinical trial of elvn-001 in cml at eha 2025 congress

Reported cumulative mmr rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving mmr by 24 weeks, which continues to compare favorably to precedent phase 1 trials of approved bcr::abl1 tkis elvn-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff enliven will host a webcast and conference call today, june 13, at 1:30 p.m. et boulder, colo.
ELVN Ratings Summary
ELVN Quant Ranking